Please use this identifier to cite or link to this item:
http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/406Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Manwani, Deepa | - |
| dc.contributor.author | Frenette, Paul S. | - |
| dc.date.accessioned | 2015-11-30T08:50:10Z | - |
| dc.date.available | 2015-11-30T08:50:10Z | - |
| dc.date.issued | 2013 | - |
| dc.identifier.uri | http://220.231.117.85:8000/handle/DHKTYTHD_123/406 | - |
| dc.description.abstract | Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin–reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review. | vi |
| dc.language.iso | en | vi |
| dc.publisher | American Society of Hematology | vi |
| dc.title | Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies | vi |
| dc.type | Article | vi |
| Appears in Collections | Huyết học = Hematology | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Hematology-2013-Manwani-362-9.pdf Restricted Access | 508.14 kB | Adobe PDF |  Request Item |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.